Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Something to note

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Aug 10, 2022 11:14am

135 Views

Post# 34884849

RE:RE:RE:Something to note

Trogarzo was a drug the FDA loved and so it had a lot of shortcuts ont he way to approval. I believe the FDA actually contributed $500,000 to Taimed to help develop the drug. Small studies, no phase III required were other benefits along with the lack of a comparison arm to their trials. This study looks to fix that last one if I am reading it right.